Pirepemat (Synonyms: IRL752)

Cat. No.: HY-137447: FAQs
Data Sheet SDS Handling Instructions

Molarity Calculator

Pirepemat (IRL752) is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat (IRL752) is used for the study of Parkinson's disease.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Pirepemat fumarate) that retains the same biological activity.

For research use only. We do not sell to patients.

Pirepemat Chemical Structure

CAS No. : 1227638-29-0

Size	Price	Stock
Solution
10 mM * 1 mL in DMSO	USD 330	Ask For Quote & Lead Time
Oil
5 mg	USD 300	Ask For Quote & Lead Time
10 mg	USD 480	Ask For Quote & Lead Time
25 mg	USD 950	Ask For Quote & Lead Time
50 mg	USD 1450	Ask For Quote & Lead Time
100 mg	USD 2550	Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Pirepemat:

Pirepemat fumarate Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Pirepemat (IRL752) is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat (IRL752) is used for the study of Parkinson's disease^[1]^[2].

In Vitro

IRL752 displayed its highest in vitro affinities for 5-HT and NA-related targets^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

IRL752 (3.7-100 µmol/kg, s.c.) has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reversed deficits resulting from hypomonoaminergic function^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal rats^[2].
Dosage:	3.7-100 µmol/kg.
Administration:	s.c., 30 min prior to testing.
Result:	Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.

Clinical Trial

Molecular Weight

213.22

Formula

C₁₁H₁₃F₂NO

CAS No.

1227638-29-0

Appearance

Oil

Color

Off-white to brown

SMILES

CO[C@]1(C(C=CC=C2F)=C2F)CCNC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Data Sheet (275 KB) SDS (251 KB) Handling Instructions (2659 KB)

References

[1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease.

[2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419. [Content Brief]

Pirepemat Related Classifications

Neurological Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pirepemat1227638-29-0IRL752IRL 752IRL-752OthersParkinson'sdiseaseinvoluntarymovementsPD-LIDspsychosisPDPInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks